Redefining clinical success in minimally invasive surgery for BPH: A composite endpoint integrating ejaculatory function, urinary improvement, and safety metrics
Objectives: Achieving both relief of urinary obstruction and preservation of ejaculatory function is a key goal of modern surgical management for benign prostatic hyperplasia (BPH). However, standardized definitions of success that integrate multiple clinical domains remain limited. This study introduces a composite definition of clinical success and explores its predictors using a multicenter dataset of minimally invasive, ejaculation-preserving procedures. Methods: Multi-institutional data were combined, including patients who underwent urethral-sparing robot-assisted simple prostatectomy (usRASP; n = 94), Aquablation ( n = 95), or Rezum ( n = 308). Complete clinical success (CSS) was defined as: (1) ⩾30% International Prostatic Symptoms Score (IPSS) reduction at 12-months; (2) preserved ejaculation, based on a positive response to the Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD Q3); and (3) absence of ⩾Grade III Clavien–Dindo complications. Partial clinical success (PCS) was defined as the achievement of any two of the three criteria. A multivariable logistic regression analysis identified independent predictors of CCS. Results: The final cohort included 497 patients. CCS rates were 66.0% (usRASP), 73.6% (Aquablation), and 68.8% (Rezum); PCS rates were 28.7%, 14.7%, and 20.1%, respectively. No significant differences were observed among groups for IPSS ( p = 0.455), ejaculation rates ( p = 0.07), or complication rates ( p = 0.445). On multivariable analysis, prostate volume < 110 mL (OR 0.52; p = 0.034), higher MSHQ-EjD Q3 (OR 1.07; p < 0.001), and shorter catheterization time (OR 0.91; p = 0.02) independently predicted CCS at 1 year. Conclusions: This composite endpoint offers a pragmatic and clinically relevant framework for evaluating success in minimally invasive BPH surgery. Its adoption may enhance cross-technique comparisons and inform individualized treatment strategies.
Authors
- Pansadoro
- Giampaolo Siena (ORCID: https://orcid.org/0000-0002-8919-0175)
- Rocco Simone Flammia (ORCID: https://orcid.org/0000-0002-3129-0544)
- Alfredo Maria Bove (ORCID: https://orcid.org/0000-0002-5139-9993)
- Sabrina De Cillis (ORCID: https://orcid.org/0000-0002-7798-6926)
- Antonio Minore (ORCID: https://orcid.org/0009-0001-5137-7380)
- R P Mastroianni
- Antonio Tufano (ORCID: https://orcid.org/0000-0003-4223-2216)
- Francesco Prata (ORCID: https://orcid.org/0000-0003-3084-6210)
- Francesco Varvello
- Maria Consiglia Ferriero
- Salvatore Basile
- Luca Ferrando
- Michele Ortenzi
- Umberto Anceschi
- Cristian Fiori
- Enrico Checcucci
- Daniele Amparore
- Luca Cindolo
- Francesco Porpiglia
- Giuseppe Simone
- Gabriele Tuderti
- Andrea Minervini
- Andrea Cocci
- Aldo Brassetti
- Giovanni Ferrari
Institutions
- Ospedale San Carlo (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Campus Bio Medico University Hospital (IT)
- Hesperia Hospital (IT)
- Candiolo Cancer Institute (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Ospedale San Luigi Gonzaga (IT)
- Fondazione Vincenzo Pansadoro (IT)
- Ospedale San Pietro Fatebenefratelli (IT)
Publication Details
- Journal
- Urologia Journal
- Published
- 2026-06-16
- DOI
- https://doi.org/10.1177/03915603261457524
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00